Pycnogenol, an antioxidant plant extract with various potential benefits for diabetes patients, may also help reduce blood sugar, claims a new study by the University of Arizona, USA, published in the May edition of the journal of Nutrition Research.
A 12-week, randomized, double-blind, placebo-controlled trial indicated the bark of the maritime pine from southwest France, known as pycongenol, could be useful as an adjunct to prescription medications for diabetes.
Ronald Watson, a lead researcher at the University, said "previous studies have shown pycnogenol supplimentation to be associated with reducing platelet aggregation, lowering low density lipoprotein and increasing high density lipoprotein cholesterol and modifying hypertension, among others. But, what really makes the study results compelling, is pycnogenol simultaneously lowered blood glucose, LDL cholesterol and blood pressure in patients. Furthermore, this is the first study suggesting that pycnogenol might also be beneficial in protecting kidney function in diabetics."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze